Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest diabetic macular edema Stories

2014-03-10 04:21:04

LEUVEN, Belgium, March 10, 2014 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a EUR3 million grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant funding will be used by ThromboGenics to support research into potential new biotherapeutics for the...

2014-03-05 08:28:36

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month...

2014-02-10 08:26:04

TARRYTOWN, N.Y., Feb. 10, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VISTA-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100, compared to...

2013-11-21 08:27:15

Many leading causes of adult-onset vision loss can be prevented TORONTO, Nov. 21, 2013 /CNW/ - According to the World Health Organization, 75 per cent of vision loss can be prevented or treated.(i) Today CNIB is launching a national campaign called "Worth a thousand words: Preserve your vision" to raise awareness of the impact of adult-onset vision loss and that many conditions are preventable if diagnosed and treated at an early stage. The campaign features a unique photo...

2013-10-07 08:25:14

GREENWOOD VILLAGE, Colo., Oct. 7, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced interim results from the ongoing 450 patient, dose finding, 505 (b) 2 study of Optina(TM) as a treatment for Diabetic Macular Edema (DME). This interim analysis was conducted by an Independent Data Review Committee (IDRC) comprised of a statistician and an ophthalmologist/retinologist, who were permitted to view the unmasked data from the trial. At least thirty...

2013-09-25 04:22:12

SOUTHAMPTON, England, September 25, 2013 /PRNewswire/ -- Consortium supported by EU Seventh Framework Programme KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), is joining a group of academic and industry researchers to undertake a project known as '3D-NET' ('Drug Discovery and Development of Novel Eye Therapeutics'). The four-year project seeks to enable the development of new drugs for the treatment of...

2013-08-26 16:25:06

VANCOUVER, Aug. 26, 2013 /PRNewswire/ - iCo Therapeutics (TSX-V: ICO), today reported financial results for the quarter ended June 30, 2013. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). "The quarter was strong both operationally and financially," said Andrew Rae, iCo's President & CEO.  "We completed the enrollment of the phase two iDEAL study initiating the countdown to our...

2013-06-18 08:30:37

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).  The study has shown a good safety profile with no drug-related serious adverse events to date. "The last patient was enrolled and treated on June 17," said Andrew Rae, President &...

2013-02-27 04:22:07

GREENWOOD VILLAGE, Colo., Feb. 27, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema. The trial will evaluate Optina(TM) in adults with recent onset diabetic macular edema. Last year, the FDA granted Optina(TM) 505(b)(2) status and drugs designated under this pathway can be approved on a single trial. (Logo:...

2013-01-22 04:21:59

GREENWOOD VILLAGE, Colo., Jan. 22, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE) announced today that the FDA has accepted the Company's IND for Optina(TM) for the treatment of diabetic macular edema (DME). Ampio plans to commence enrollment in a clinical trial in the first quarter of 2013. The FDA granted Optina(TM) 505(b)(2) status in July, 2012. Drugs designated under this pathway can be approved on a single trial. (Logo:...